Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research Grade Andecaliximab | Login | Research Grade Andecaliximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Elgemtumab | Login | Research Grade Elgemtumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Lumretuzumab | Login | Research Grade Lumretuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Duligotuzumab | Login | Research Grade Duligotuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Patritumab | Login | Research Grade Patritumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Seribantumab | Login | Research Grade Seribantumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Emibetuzumab | Login | Research Grade Emibetuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Onartuzumab | Login | Research Grade Onartuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Telisotuzumab | Login | Research Grade Telisotuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Abagovomab | Login | Research Grade Abagovomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Igovomab | Login | Research Grade Igovomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Oregovomab | Login | Research Grade Oregovomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Sofituzumab | Login | Research Grade Sofituzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Demcizumab | Login | Research Grade Demcizumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Enoticumab | Login | Research Grade Enoticumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Navicixizumab | Login | Research Grade Navicixizumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Dilpacimab | Login | Research Grade Dilpacimab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Farletuzumab | Login | Research Grade Farletuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Mirvetuximab | Login | Research Grade Mirvetuximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Indusatumab | Login | Research Grade Indusatumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Anetumab | Login | Research Grade Anetumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Amatuximab | Login | Research Grade Amatuximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Enapotamab | Login | Research Grade Enapotamab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Tilvestamab | Login | Research Grade Tilvestamab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Pasotuxizumab | Login | Research Grade Pasotuxizumab | ||||||||||||||||
|
||||||||||||||||||


